Navigation Links
Inostics' Blood-based Mutation Testing Receives CLIA Certification
Date:5/30/2013

BALTIMORE, May 30, 2013 /PRNewswire/ --

Inostics, a molecular diagnostics company that provides blood-based mutation testing, received CLIA (Clinical Laboratory Improvement Amendments) licensure for its clinical laboratory located in Baltimore, MD. This marks a critical milestone for the clinical adoption of this non-invasive molecular approach for the analysis of tumor biomarkers.

"Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making. We are extremely excited to be able to bring this solution to cancer patients as OncoBEAM tests offer a significant enhancement to clinical care over traditional tissue-based molecular testing," Dr. Frank Diehl , CSO of Inostics, said.

The OncoBEAM blood test is based on BEAMing technology which combines emulsion based digital PCR with flow cytometry. This technology enables the molecular analysis of tumor DNA shed from primary and metastatic tumors, found circulating in the blood of patients. Due to its non-invasiveness, OncoBEAM blood tests introduce new possibilities for the management of various cancers like skin, colorectal, breast, and lung cancer. Now a simple blood draw can support clinical decision making in the context of therapy selection, assessment of drug response, resistance and recurrence monitoring, and detection of minimal residual disease (MRD).  

About Inostics

Inostics is a molecular service company whose core competency is mutation detection utilizing highly sensitive technologies such as BEAMing and Plasma-Sequencing. In addition to the CLIA services, Inostics serves pharmaceutical companies and researchers with testing services for plasma/serum and tissue samples in the field of clinical trials and research in oncology. Inostics' headquarters are located in Hamburg, Ger
'/>"/>

SOURCE Inostics GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inostics DNA Blood Test Provides a More Precise Picture of Resistance Mutations Than Traditional Biopsies
2. DioGenix and Fast Forward Collaborate to Develop Blood-Based Molecular Diagnostic for Multiple Sclerosis
3. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
4. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
5. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
6. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
7. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
8. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
9. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
10. SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
11. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... HILL, N.C. , Feb. 27, 2015 ... over the past decade but one thing hasn,t changed: ... MSLs to build relationships with Key Opinion Leaders. ... recognized as the most valuable type of interaction, field ... limits on their KOL interactions. This is just one ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... from a pre-clinical study published in the ... ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ... (a checkpoint inhibitor), suppression of tumor growth was ... when treating certain hematologic cancers and solid tumors ...
(Date:2/27/2015)... TEL-AVIV , Israele, February 27, 2015 /PRNewswire/ ... continua nel suo sviluppo dell,innovativo sistema di monitoraggio ... il primo trial sull,uomo-   ... operante nello sviluppo di nuovo sistema per il ... congestizio (CHF), ha annunciato oggi di aver concluso ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... ResMed Inc. (NYSE: RMD ) today announced results ... quarter ended September 30, 2011 was a record $314.8 million, ... basis) over the quarter ended September 30, 2010.  For the ... Largely as a result of currency exchange rate movements, net ...
... of the most crucial components of a successful new ... relationships with the FDA. However, while building a collegial and ... the FDA is not always an easy task, not doing ... study participant, a Regulatory Affairs Executive Director at a leading ...
Cached Medicine Technology:ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 2ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 3ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 4ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 5ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 6Recent Research Provides Formula for Timely Product Launch: Good Science + Effective FDA Relations 2
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 A study ... promising new gene therapy procedure for the treatment of ... in patients. Authored by Dr. Robert MacLaren, ... published in the Lancet Medical Journal on January 16, ... choroideremia, a rare genetic disorder that mostly affects men ...
(Date:2/28/2015)... February 28, 2015 Dr. Perry ... Coast area residents, recently announced a special offer for ... a treatment option for new and established patients at ... with a bright, white smile, Dr. Patel and his ... $299, marked down from the regular price of $450. ...
(Date:2/28/2015)... York, NY (PRWEB) February 28, 2015 On ... Phishing Kits Make It Easy For Scammers To Steal Your ... anyone can get their hands on a DIY phishing kit, ... But it also touched on another important point about how ... these kits are often implemented, “like compromising legitimate content management ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
... FRIDAY, March 18 (HealthDay News) -- Obstructive sleep apnea may ... with enlarged prostates, a new study suggests. The study ... benign prostate enlargement (BPE) and reported nighttime urination (nocturia) at ... of same-age men who had no BPE and one or ...
... 18 (HealthDay News) -- Women in smoke-free homes and ... breast cancer, new research shows. U.S. researchers compared ... of breast cancer incidence and death. States with higher ... breast cancer deaths, particularly among younger premenopausal women. ...
... College of Radiology,s Imaging Network (ACRIN) and the ... (NCI) Clinical Trials Cooperative Group members, today announced ... programs. The groups plan to form ... new organization will include three areas of research ...
... with different terms to describe a clinical trial, parents were far ... called a "research study" than if it was called a "medical ... the former as safer, even though that was not necessarily the ... Human Research . Terms such as these are ...
... News) -- Anti-drug ads appear to be an effective way ... the United States, a new study has found. In ... Influence" anti-drug campaign, researchers analyzed the relationship between exposure to ... students in grades 8, 10 and 12. The campaign ...
... The federal Centers for Disease Control and Prevention ... Health & Hospitals System and Rush University Medical ... successful program aimed at preventing healthcare-associated infections, antibiotic ... The project, dubbed the Chicago Antimicrobial Resistance and ...
Cached Medicine News:Health News:Sleep Disorder May Spur Men to Head to Bathroom at Night 2Health News:Biomarker-driven science at the heart of new ACRIN-ECOG structure 2Health News:Biomarker-driven science at the heart of new ACRIN-ECOG structure 3Health News:Terminolgy matters in parents' willingness to enroll their children in research 2Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 2Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 3Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: